Obtain Lateral Spine Imaging Immediately to Detect Vertebral Fractures
A 5 cm height loss with normal BMD is highly suspicious for vertebral fractures and mandates immediate lateral spine imaging with either standard radiography or vertebral fracture assessment (VFA) by DXA. This height loss meets the threshold for imaging regardless of BMD results, as vertebral fractures indicate skeletal fragility and high future fracture risk even when bone density appears normal 1.
Why Normal BMD Doesn't Rule Out Fractures
Most fragility fractures occur in individuals with T-scores higher than -2.5, confirming that BMD alone is insufficient for assessing skeletal fragility 2. The presence of a vertebral fracture changes your diagnostic classification, estimated future fracture risk, and clinical management—even with normal bone density 1.
Immediate Imaging Indications
Your patient meets clear guideline criteria for lateral spine imaging with historical height loss >4 cm (>1.5 inches) 1. The guidelines specify this threshold when T-score is less than -1.0, but given the magnitude of height loss (5 cm), imaging is warranted to rule out vertebral fractures that would fundamentally alter management.
Imaging Options:
- Vertebral Fracture Assessment (VFA) by DXA - can often be performed at the same time as BMD measurement with minimal radiation exposure, patient inconvenience, and cost 2, 1
- Standard lateral spine radiography - if VFA unavailable or if confirmation needed
If Vertebral Fracture is Confirmed
Initiate pharmacologic treatment immediately. Vertebral fractures indicate:
- Compromised bone strength requiring intervention 2
- Approximately 2-fold increased risk of future fractures 2
- Highest fracture risk in the immediate 1-2 years following detection (imminent fracture risk) 2
- Qualification for treatment regardless of BMD values 1
Complete Secondary Osteoporosis Workup
While awaiting imaging, obtain comprehensive laboratory evaluation 1:
Essential labs:
- Complete blood count
- Comprehensive metabolic panel (calcium, phosphate, liver enzymes, alkaline phosphatase, creatinine)
- 25-hydroxyvitamin D
- Intact parathyroid hormone (PTH)
- 24-hour urine collection for calcium, sodium, and creatinine (after vitamin D repletion and on 1,000-1,200 mg/day calcium intake for ≥2 weeks)
Additional testing if clinically indicated:
- TSH if on thyroid hormone or hyperthyroidism suspected
- Celiac antibodies (tissue transglutaminase)
- Serum protein electrophoresis if myeloma suspected
Common Pitfall to Avoid
Do not be falsely reassured by normal BMD. The "osteoporosis care gap" exists precisely because clinicians fail to recognize that fragility fractures—indicated by significant height loss—represent skeletal fragility requiring treatment independent of BMD values 2. Approximately 70% of high-risk individuals remain untreated due to this oversight 2.
Monitoring Considerations
If vertebral fractures are confirmed and treatment initiated, consider bone turnover markers (CTX and PINP) at 3-6 months to provide early feedback on treatment efficacy rather than waiting 2 years for repeat DXA 1. However, note that a recent fracture will transiently raise these markers, so interpretation must account for timing 1.